High Quality Fenofibrate Raw Powder

CAS:49562-28-9

MF:C20H21ClO4

MW:360.83 

EINECS:256-376-3

Specification: 99% min Fenofibrate Powder

Sample: Fenofibrate Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Fenofibrate Powder Usage and Synthesis.

Fenofibrate is a kind of lipid-lowering drug, the main mechanism of action is to inhibit HMG-CoA reductase, reduce cholesterol synthesis in the cell, so as to reduce blood lipids.

Fenofibrate is suitable for the treatment of endogenous hypertriglyceridemia and primary hypercholesterolemia, etc. It has been widely used in the United States, France, Japan and other countries, and now it has become the first choice of drugs for the treatment of hyperlipidemia.

Fenofibrate is significantly better than statins in lowering TG and raising HDL-C. Since simple dyslipidaemia is rare in diabetic patients, whose common lipid profile is increased TC, decreased HDL-C, and increased or normal LDL-C, fenofibrate is clinically effective in the treatment of dyslipidaemia in diabetic patients.

Recent studies have shown that fenofibrate also has anti-tumour effects, fenofibrate inhibits the expression of tumour necrosis factor (TNF-α) and interleukin-6 (IL-6) factor monocytes via PPAR-α receptor and promotes the differentiation as well as apoptosis of tumour cells.

Fenofibrate had global sales of RMB 246 million in 2018.

Uses and functions of Fenofibrate.

Fenofibrate belongs to the fibrate class of antilipidemia drugs, which has strong efficacy and significant cholesterol-lowering and triglyceride lowering effects, but the adverse reactions are small. High levels of this type of fat in the blood have been linked to an increased risk of atherosclerosis (clogged arteries).

Fenofibrate used in combination with a proper diet can help treat high cholesterol and high triglycerides.

In addition to eating an appropriate diet (e.g., a low cholesterol/low-fat diet), other lifestyle options that may contribute to the efficacy of fenofibrate include exercise, overweight weight loss, and smoking cessation.

Pharmacological Effects of Fenofibrate.

1.Lipotropic effect

Fenofibrate can reduce the total triglyceride (TG) level by 25% to 59%, increase the level of high-density lipoprotein-cholesterol (HDL-C) by 1% to 34%, and decrease the level of total cholesterol (TC) by 6% to 27%, and it is clinically used for the treatment of hyperlipidaemia with elevated TG or mixed hyperlipidaemia with predominantly elevated TG and hyperlipidaemia with low HDL-C.

Fenofibrate is significantly superior to statins in its efficacy in lowering TG and elevating HDL-C. Since simple dyslipidaemia is rare in diabetic patients, whose common lipid profile is increased TC, decreased HDL-C, and increased or normal low-density lipoprotein-cholesterol (LDL-C), fenofibrate is clinically effective in the treatment of dyslipidaemia in diabetic patients.

In addition, due to the different mechanism of action of fenofibrate and statins, statins can significantly reduce TC and LDL-C, and the combination of the two can form a complementary therapeutic effect. Therefore, fenofibrate can be used in combination with statins such as atorvastatin and simvastatin to adjust the lipid profile of patients with mixed hyperlipidaemia.

2. Non-lipid regulating effect

In addition to its lipid-regulating effects, fenofibrate has anti-inflammatory, fibrinogen-lowering and prophylactic neuroprotective effects, and is therefore useful in reducing the risk of cardiovascular disease.

Fenofibrate's unique non-lipotropic effects include enhancing insulin sensitivity, increasing bone density, improving microalbuminuria and ameliorating hyperuricaemia, which may simultaneously improve the patient's multimorbidities. Therefore, fenofibrate is particularly suitable for regulating dyslipidaemia in patients with type 2 diabetes or metabolic syndrome.

3.Anti-tumour effects

Fenofibrate inhibits the expression of tumour necrosis factor (TNF-α) and interleukin-6 (IL-6) in monocytes through PPAR-α receptor and promotes the differentiation as well as apoptosis of tumour cells.

Production method of Fenofibrate Powder.

Fenofibrate is isopropyl 2-methyl-2-[4-(4-chlorobenzoyl)phenoxy]propionate, containing not less than 98.5% of C20H21ClO4, calculated as dry product.